Microcap Ledger Inmune Bio, Inc. $INMB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Boca Raton, FL
- Fiscal year end
- December 31
- Shares outstanding
- 27,753,789 [10-Q 2026-08-06]
What the company doesAI summary of filing
INmune Bio is a clinical-stage biotechnology company developing cell and protein therapies designed to reprogram the innate immune system for diseases driven by chronic inflammation and immune dysfunction. The company's lead program is CORDStrom, a pooled human umbilical cord-derived mesenchymal stromal cell therapy for recessive dystrophic epidermolysis bullosa (RDEB), which has completed a pivotal clinical trial and the company intends to file for regulatory approval in the United Kingdom, European Union, and United States in 2026. The company is also advancing XPro1595, a protein therapeutic targeting neuroinflammation in Alzheimer's disease, which completed Phase II testing, and INKmune, a natural killer cell-priming platform for cancer treatment currently in Phase II. INmune Bio is pre-revenue and does not currently plan to independently advance XPro or INKmune into later-stage development. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$6.68M | −$6.58M | $18.41M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $50.0K | −$46.00M | −$22.58M | $24.75M | [10-K 2026-03-30] |
| FY ended Dec 2024 | $14.0K | −$42.00M | −$33.36M | $20.92M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$3.29M
- Cash runway Estimate
- ~16.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 22,172,451 | [10-Q 2024-10-31] |
| 2025-03-27 | 22,930,311 | [10-K 2025-03-27] |
| 2025-05-08 | 23,210,377 | [10-Q 2025-05-08] |
| 2025-08-07 | 26,585,258 | [10-Q 2025-08-07] |
| 2025-10-30 | 26,585,258 | [10-Q 2025-10-30] |
| 2026-03-30 | 26,585,258 | [10-K 2026-03-30] |
| 2026-05-07 | 26,585,258 | [10-Q 2026-05-07] |
| 2026-08-06 | 27,753,789 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2024-05-01; declared effective 2024-08-07 [S-3 2024-05-01]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-02 | Juda Scott | exercise | 14,801 | $1.40 | [4 2026-07-07] |
| 2026-07-02 | Lowdell Mark William | exercise | 7,211 | $1.40 | [4 2026-07-07] |
| 2026-07-02 | Moss David J | exercise | 9,014 | $1.40 | [4 2026-07-07] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-14 | 8-K | Director or officer change; Other events |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-31 | 8-K | Other events |
| 2026-07-01 | 8-K | Material agreement entered |
| 2026-06-23 | 8-K | Other events |
| 2026-06-17 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-02 | 8-K | Other events |
| 2026-05-14 | 8-K | Other events |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-05 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-04-23 | DEF 14A | Proxy statement |
| 2026-03-30 | 10-K | Annual report |
Alerts for $INMB
Email me when Inmune Bio, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.